Lonza adds microbial plant for Servier partnership


ZURICH, Aug 4 (Reuters) - Swiss contract manufacturer Lonza Group LONN.S is adding a mid-scale microbial facility to supply France's Laboratoires Servier with active pharmaceutical ingredient for acute lymphoblastic leukaemia therapies, Lonza said on Tuesday.

The new facility will go online in the second half of 2022, with 100 new staff to be recruited, Lonza added in a statement.

(Reporting by Michael Shields Editing by Michelle Martin)

((Michael.Shields@thomsonreuters.com; +41 58 306 7461; Reuters Messaging: michael.shields.thomsonreuters.com@reuters.net))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.